Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Head and neck

1675 - Oncological outcome following intensification of treatment by Transoral robotic surgery (TORS) for HPV negative Stage IV Oropharyngeal cancer: A prospective trial. (338O)


18 Nov 2017


Head and neck


Surgical Oncology;  Radiation Oncology;  Head and Neck Cancers


Karan Gupta


Annals of Oncology (2017) 28 (suppl_10): x100-x110. 10.1093/annonc/mdx665


K. Gupta, S. Dabas

Author affiliations

  • Department Of Head-neck And Thoracic Surgical Oncology, Fortis Memorial Research Institute, 122002 - Gurgaon/IN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1675


To see long-term oncological outcome of Transoral Robotic Surgery for intensification of treatment in addition to adjuvant Radiotherapy/chemoradiotherapy for Stage IV HPV negative oropharyngeal malignancies.


From March 2013 to September 2015, 86 patients with Stage IV (cT1-3N2) HPV negative oropharyngeal carcinoma underwent TORS & neck dissection using daVinci® Surgical system. After TORS, patients received adjuvant radiation or chemoradiation. Patients were followed and evaluated for disease free survival and overall survival.


A total of 86 patients (69 males and 17 females) underwent TORS. All patients were HPV negative. Mean age at presentation was 57.4 years (32-83 years). Escalation of therapy with TORS followed by 60-64Gy ± 5-6 cycles weekly Inj. cisplatin adjuvant RT/CTRT lead to better survival rates as compared to CTRT/RT alone. T1-3N2a: 12 patients: All underwent TORS followed by RT in 7 patients and CTRT in 5 patients. Ten patients are disease free and alive on an average follow-up of 29 months with two patients developed nodal recurrence, but are alive after salvage surgery. T1-3N2b: 56 patients: After TORS, 40 patients received CTRT and 16 patients received only RT. 46 (82.1%) are alive and disease free. Six patients developed loco-regional recurrence of which 4 patients were salvaged and disease free. Four patients expired due to metastasis T1-3N2c: 18 patients: After TORS, 13 received adjuvant CTRT and 5 received RT. 10 (55.6%) were disease free and alive. Seven patients developed locoregional recurrence of which 4 are disease free and alive after salvage surgery. 3 patients expired due to disease. Of 86 patients with Stage IVa Oropharyngeal Carcinoma, escalation of treatment with TORS followed by adjuvant CTRT/RT gave disease free survival of 76.7% and an overall survival of 88.4% on a mean follow-up of 34 months (21-51 months).


Transoral Robotic Surgery is a good option for cure in relatively radio-resistant HPV negative resectable oropharyngeal malignancies. TORS can be used to intensify treatment of Stage IV oropharyngeal carcinoma and avoid early and late toxicities due to higher doses of RT/CRT and achieve better oncological outcome.

Clinical trial identification

Legal entity responsible for the study

FMRI, Gurgaon




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.